Higher Level of Mismatch in APOE ε 4 Carriers for Amyloid-Beta Peptide Alzheimer’s Disease Biomarkers in Cerebrospinal Fluid
Open Access
- 1 January 2019
- journal article
- research article
- Published by Taylor & Francis in ASN Neuro
- Vol. 11 (1)
Abstract
Cerebrospinal fluid (CSF) biomarkers are widely used in the diagnosis of dementia. Even though there is a causal correlation between apolipoprotein E (APOE) genotype and amyloid-beta (Aβ), the determination of APOE is currently not supported by national or international guidelines. We compared parallel measured CSF biomarkers of two independent laboratories from 126 patients who underwent clinical dementia diagnostics regarding the APOE genotype. APOE ε4 reduces Aβ1-42 (Aβ42) and Aβ42 to Aβ 1-40 ratio (Aβ42/40) but not total Tau or phospho-181 Tau CSF levels. Higher discordance rates were observed for Aβ42 and subsequently for Aβ42/40 in APOE ε4 carriers compared with noncarriers, and the correlation between the two laboratories was significantly lower for Aβ42 in APOE ε4 positive patients compared with patients without APOE ε4. These observations demonstrate that the evaluation of CSF Aβ biomarkers needs to be interpreted carefully in the clinical context. Different immunoassays, disparate cutoff values, and APOE should be respected.Keywords
This publication has 18 references indexed in Scilit:
- International Work Group Criteria for the Diagnosis of Alzheimer DiseaseMedical Clinics of North America, 2013
- Cerebrospinal fluid APOE levels: an endophenotype for genetic studies for Alzheimer's diseaseHuman Molecular Genetics, 2012
- Apolipoprotein E genotyping method by Real Time PCR, a fast and cost-effective alternative to the TaqMan® and FRET assaysJournal of Neuroscience Methods, 2009
- Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analysesNature Reviews Neuroscience, 2008
- Apolipoprotein E levels in cerebrospinal fluid and the effects of ABCA1polymorphismsMolecular Neurodegeneration, 2007
- Utility of the Apolipoprotein E Genotype in the Diagnosis of Alzheimer's DiseaseNew England Journal of Medicine, 1998
- Characterization of stable complexes involving apolipoprotein E and the amyloid β peptide in Alzheimer's disease brainNeuron, 1995
- Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease.Proceedings of the National Academy of Sciences, 1993
- Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease.Proceedings of the National Academy of Sciences, 1993
- Apolipoprotein E: A pathological chaperone protein in patients with cerebral and systemic amyloidNeuroscience Letters, 1992